Celsion Corporation  

(Public, NASDAQ:CLSN)   Watch this stock  
Find more results for CLSN
0.00 (0.00%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.18 - 2.28
52 week 2.15 - 4.03
Open 2.20
Vol / Avg. 29,602.00/70,567.00
Mkt cap 44.15M
P/E     -
Div/yield     -
EPS -1.27
Shares 19.98M
Beta 1.81
Inst. own 29%
Mar 11, 2015
Q4 2014 Celsion Corp Earnings Release (Estimated) Add to calendar
Nov 11, 2014
Q3 2014 Celsion Corp Earnings Call
Nov 11, 2014
Q3 2014 Celsion Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -5553.88% -1650.27%
Operating margin -5335.03% -3082.30%
EBITD margin - -3014.45%
Return on average assets -36.36% -23.23%
Return on average equity -66.08% -59.11%
Employees 13 -
CDP Score - -


Suite 100, 997 Lenox Drive
United States - Map
+1-609-8969100 (Phone)
+1-609-8962200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. As of December 31, 2011, the Company's product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer. ThermoDox is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a range of cancers. Localized heat at mild hyperthermia temperatures releases the encapsulated doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in and around the targeted tumor. In June 2014, it acquired all of the assets of EGEN Inc.

Officers and directors

Jeffrey W. Church CPA Chief Financial Officer, Senior Vice President - Corporate Strategy and Investor Relations
Age: 57
Bio & Compensation  - Reuters
Khursheed Anwer Ph.D. Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
Age: 55
Bio & Compensation  - Reuters
Nicholas Borys M.D. Vice President, Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Michael H. Tardugno Executive Chairman of the Board, President, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Pok Yu Chow Ph.D. Independent Director
Bio & Compensation  - Reuters
Frederick J. Fritz Independent Director
Age: 63
Bio & Compensation  - Reuters
Robert W. Hooper Independent Director
Age: 67
Bio & Compensation  - Reuters
Alberto R. Martinez M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters